Brief Article
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Oct 28, 2009; 15(40): 5097-5102
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5097
Table 3 Demographic & baseline characteristics (Safety analysis: n = 64)
ItemSubjects
n%
Age at baseline (yr)20-3911.6
40-643453.1
≥ 652945.3
SexMale2742.2
Female3757.8
DiagnosisGastric ulcer5789.1
Duodenal ulcer46.3
Gastric/duodenal ulcer23.1
Anastomotic ulcer11.6
Ulcer historyInitial occurrence2945.3
Reoccurrence2031.3
Unknown1523.4
Prior historyNo4773.4
Yes1726.6
History of allergiesNo5585.9
Yes69.4
Unknown34.7
Type of NSAID (duplicates included)Diclofenac sodium3453.1
Loxoprofen sodium2031.3
Other2742.2
Anti-ulcer treatment before rabeprazole treatment (within 1 mo)No1929.7
Yes4570.3
Concomitant medication (not including NSAIDs)No710.9
Yes5789.1
Endoscopic findings before start of treatment (ulcer size)3 ≤ size < 10 mm3148.4
10 ≤ size < 20 mm2539.1
≥ 20 mm57.8
Unknown34.7
Rabeprazole treatment duration ≤ 56 d2742.2
(gastric ulcer, gastric/duodenal ulcer, duodenal ulcer, anastomotic ulcer)> 56 d3757.8
Rabeprazole dosage10 mg3960.9
20 mg1929.7
10 mg→20 mg11.6
20 mg→10 mg57.8